Mammography, Early Detection Biomarkers, Risk Assessment, and Imaging Technologies, MERIT Study
MERIT (Mammography, Early Detection Biomarkers, Risk Assessment, and Imaging Technologies) Cohort
2 other identifiers
observational
10,000
1 country
1
Brief Summary
This study collects mammogram images, blood samples, and clinical information from women undergoing routine screening mammograms. Creating a bank of blood samples and a database of clinical and risk information may be used in future research related to breast cancer, other cancers, and women's health.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2017
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 15, 2017
CompletedFirst Submitted
Initial submission to the registry
December 11, 2017
CompletedFirst Posted
Study publicly available on registry
January 24, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
April 30, 2027
February 19, 2026
February 1, 2026
9.6 years
December 11, 2017
February 17, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Creation of a repository of blood specimens and database of imaging, clinical data, health measurements, and questionnaire data
5 years
Study Arms (1)
Observational (mammography, questionnaires, blood collection)
Participants complete questionnaires over 15-25 minutes about personal and family history of cancer, health status, breast cancer risk factors, diet, weight gain, and physical activity, and undergo collection of blood samples at baseline and then annually for 5 years. Participants also undergo standard of care mammography at baseline and then annually for 5 years.
Interventions
Undergo collection of blood samples
Undergo standard of care mammography
Complete questionnaires
Eligibility Criteria
Participants receiving screening mammograms at MD Anderson site
You may qualify if:
- Willingness to participate in the study and ability to provide informed consent
- Willingness to complete a questionnaire and to provide a blood sample at the initial visit and at follow up annual visits
- Undergoing a screening mammogram at participating sites. Subjects undergoing routine annual diagnostic mammograms or CEM as part of a screening study are also eligible.
You may not qualify if:
- Current or recent (within the prior 6 months) history of breast feeding
- Personal history of breast cancer (ductal breast carcinoma in situ \[DCIS\] or invasive breast cancer)
- Personal history of any other cancer (excluding in-situ, stage 0, and non-melanoma skin cancers and other pre-cancerous conditions) treated within the last 5 years.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- M.D. Anderson Cancer Centerlead
- National Cancer Institute (NCI)collaborator
Study Sites (1)
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Related Links
Biospecimen
Blood
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jessica W Leung
M.D. Anderson Cancer Center
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 11, 2017
First Posted
January 24, 2018
Study Start
September 15, 2017
Primary Completion (Estimated)
April 30, 2027
Study Completion (Estimated)
April 30, 2027
Last Updated
February 19, 2026
Record last verified: 2026-02